How we treat neurological toxicity from immune checkpoint inhibitors.
Loading...
Embargo End Date
ICR Authors
Authors
Spain, L
Tippu, Z
Larkin, JM
Carr, A
Turajlic, S
Tippu, Z
Larkin, JM
Carr, A
Turajlic, S
Document Type
Journal Article
Date
2019-07-01
Date Accepted
2019-06-17
Abstract
Neurological adverse events from immune checkpoint inhibition are increasingly recognised, especially with combination anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) and anti-programmed death receptor 1 (anti-PD-1) therapies. Their presenting symptoms and signs are often subacute and highly variable, reflecting the numerous components of the nervous system. Given the risk of substantial morbidity and mortality, it is important to inform patients of symptoms that may be of concern, and to assess any suspected toxicity promptly. As with other immune-related adverse events, the cornerstone of management is administration of corticosteroids. Specialist neurology input is vital in this group of patients to guide appropriate investigations and tailor treatment strategies.
Citation
ESMO Open, 2019, 4 (Suppl 4), pp. e000540 -
Source Title
ESMO Open
Publisher
ELSEVIER
ISSN
2059-7029
eISSN
2059-7029
2059-7029
2059-7029
Collections
Research Team
Melanoma & Kidney Cancer